Cybin Inc. (CYBN)
(Delayed Data from AMEX)
$0.27 USD
0.00 (0.26%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.27 0.00 (0.75%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.27 USD
0.00 (0.26%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.27 0.00 (0.75%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
What Makes Cybin Inc. (CYBN) a New Buy Stock
by Zacks Equity Research
Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
by Zacks Equity Research
Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
by Kanishka Das
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Brian's Big Idea on Biotech
by Brian Bolan
A look at drugs for drug addiction and the biotech space.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Bull Of The Day: Cybin (CYBN)
by Brian Bolan
Instead of a hangover, the side effect from this treatment has been described as an "after glow."
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
by Zacks Equity Research
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.